ReviewFrontiers in immunology2026
The hormone-microbiota-NET framework in gynecologic diseases: evidence, controversies, and translational opportunities.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gynecologic diseases, including infectious disorders, endocrine-related conditions, gynecologic malignancies, and pregnancy complications, are clinically diverse yet frequently share features of hormonal imbalance, microbial dysbiosis, and dysregulated inflammation. Current research has largely examined these processes separately, limiting integrated understanding of their potential interactions. This review synthesizes current evidence and proposes a hormone-microbiota-neutrophil extracellular trap (NET) framework as a conceptual tool for understanding common and disease-specific mechanisms across gynecologic disorders. We first summarize the core molecular basis of NET formation, with emphasis on peptidylarginine deiminase 4 as a candidate regulatory node. We then examine the effects of sex hormones on NET regulation, the role of the microbiota in shaping mucosal immune responses, and potential mechanistic links between microbial products, extracellular matrix components, and NET dysregulation. Evidence is further integrated across representative infectious, endocrine-related, malignant, and pregnancy-associated conditions, including pelvic inflammatory disease, bacterial vaginosis, endometriosis, polycystic ovary syndrome, ovarian, cervical, and endometrial cancers, and preeclampsia. The available literature indicates that hormone-dependent immune modulation, pathogen- or microbiota-associated inflammatory signaling, and NET-related tissue injury may converge in multiple gynecologic settings, although the strength of evidence differs substantially across specific pathways and diseases. Direct support is strongest for selected hormone-NET effects in defined experimental or pregnancy-associated settings and for pathogen/microbial product-NET interactions in infectious contexts, whereas the complete hormone-microbiota-NET framework and the proposed glycosaminoglycan-peptidylarginine deiminase 4 (GAG-PAD4) bridge remain insufficiently validated. Overall, this review provides an evidence-based integrative framework for organizing current knowledge, identifying mechanistic gaps, and informing future biomarker development, patient stratification, and translational research in gynecologic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.